These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 899024)

  • 1. [Qualitative analysis of the binding of fibrin in organic tissue (author's transl)].
    Braun F; Wernisch J; Spängler HP; Holle J
    Wien Klin Wochenschr; 1977 Jul; 89(14):489-94. PubMed ID: 899024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
    Sakata Y; Aoki N
    J Clin Invest; 1980 Feb; 65(2):290-7. PubMed ID: 6444305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
    Idell S
    Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plasminogen-binding centers of molecules of fibrinogen, fibrin and products of their proteolysis].
    Grinenko TV; Tret'iachenko VG; Kudinov SA; Medved' LV
    Biokhimiia; 1987 Oct; 52(10):1732-9. PubMed ID: 3427134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
    von dem Borne PA; Cox LM; Bouma BN
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glycosoaminoglycans of the connective tissue (author's transl)].
    Tomaszewski J
    Postepy Biochem; 1973; 19(3):447-69. PubMed ID: 4270459
    [No Abstract]   [Full Text] [Related]  

  • 7. [Kinetics of fibrin lysis by plasmin: inhibition by fibrin degradation products].
    Zhitkova IuV; Aĭsina RB; Varfolomeev SD
    Bioorg Khim; 1996 Dec; 22(12):911-5. PubMed ID: 9054342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.
    Pizzo SV; Schwartz ML; Hill RL; McKee PA
    J Clin Invest; 1972 Nov; 51(11):2841-50. PubMed ID: 4263497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease.
    Adány R; Szegedi A; Ablin RJ; Muszbek L
    Thromb Haemost; 1988 Oct; 60(2):293-7. PubMed ID: 3064359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J; Kimura S; Aoki N
    J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of plasminogen with polymerizing fibrin and its derivatives, monitored with a photoaffinity cross-linker and electron microscopy.
    Weisel JW; Nagaswami C; Korsholm B; Petersen LC; Suenson E
    J Mol Biol; 1994 Jan; 235(3):1117-35. PubMed ID: 8289311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Electron microscopic observations on fibrinogenesis in the reticular connective tissue between individual skeletal muscle fibers].
    Magari S
    Acta Anat (Basel); 1969; 72(1):50-62. PubMed ID: 5799962
    [No Abstract]   [Full Text] [Related]  

  • 14. The binding of tumor localizing porphyrins to a fibrin matrix and their effects following photoirradiation.
    Musser DA; Wagner JM; Weber FJ; Datta-Gupta N
    Res Commun Chem Pathol Pharmacol; 1980 Jun; 28(3):505-25. PubMed ID: 7403664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis.
    Reed GL; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1991; 104():21-8. PubMed ID: 1845147
    [No Abstract]   [Full Text] [Related]  

  • 16. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma.
    He S; Zhu K; Skeppholm M; Vedin J; Svensson J; Egberg N; Blombäck M; Wallen H
    Thromb Haemost; 2007 Oct; 98(4):871-82. PubMed ID: 17938814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrin deposition in primary and metastatic human brain tumours.
    Bárdos H; Molnár P; Csécsei G; Adány R
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):536-48. PubMed ID: 8874864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of urinary protein C inhibitor to fibrin(ogen) and its binding mechanism.
    Hayashi S; Yamada K
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):153-8. PubMed ID: 8384496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the binding to fibrin of urokinase and tissue plasminogen activator.
    Thorsen S; Glas-Greenwalt P; Astrup T
    Thromb Diath Haemorrh; 1972 Aug; 28(1):65-74. PubMed ID: 4672651
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
    Reed GL; Matsueda GR; Haber E
    Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.